Home > Boards > Free Zone > Penny Fundamentals > Stock Room
Followed By 396
Posts 17870
Boards Moderated 1
Alias Born 06/07/2018

Sunday, October 03, 2021 2:06:35 PM

Re: None

Post# of 13037
$CHNC CHNC to Seek Up to $3 Million Funding for Expansion of Existing Product Lines and Development of New Cannabis-Derived Therapeutics
Press Release | 10/01/2021
HOUSTON, TX, Oct. 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- China Infrastructure Construction Corp. (OTC: CHNC) (dba Cannabis Bioscience International Holdings), announced today that it is actively seeking strategic partners to invest up to $3 million in two or three tranches although there can be no assurance that any such investment can be obtained on acceptable terms, or at all. The company has been diligently working around the clock actively entertaining proposals from quality groups that will bring proprietary knowledge and expertise to support and accelerate its ongoing revenue streams and build new revenue-generating centers in the U.S. and internationally.

“Our first priority is to continue to solidify the foundation of our existing digital products and services such as our Cannabis World Journals, eBooks, educational videos, sleep center and clinical studies,” said Henry Levinski, CHNC´s Treasurer. “We have set challenging goals in all of these areas and are determined to reach or exceed them; for example, we will continue to gain our proper share of the market by featuring our products in new languages such as Mandarin, French, German and Hindi.”

The company will continue to invest in its internal staff of associates, which has grown from approximately 20 to over 60 within the past year. “We are very proud of the team we have built, and we intend to continue to add value through our association of professionals all striving for our common goal of stability and growth,” said Anne Graham, CHNC’s Corporate Attorney and VP of Operations. “With this additional funding we have set a goal of building our staff to 250 by the third quarter of 2022.”

Furthermore, we will also use part of this funding to start research on the medical benefits of cannabis and the implication of cannabinoids on body homeostasis with a 18-months clinical trial on healthy individuals and patients with pathologies associated with endocannabinoid system disorders; this research aims to provide the scientific data required to establish cannabis as a safe and effective alternative in various diseases.

More importantly, we will move to establish a manufacturing facility for a number of medical, nutraceutical, and vitamin supplement products utilizing therapeutic derivatives of cannabis to assist patients suffering from diseases such as cancer, multiple sclerosis, epilepsy and many more. We are committed to working within U.S. and international laws and will only develop and distribute our products and services accordingly.

Certainly, one of the characteristics of CHNC is innovation and we are convinced that investment focused on these areas will allow us to grow and continue to yield the investment-returns (ROI) experienced so far by our investors and much more. To learn more visit: https://www.chnc-hdh.com/

Safe Harbor Statement

The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words "may," "will," "should," "plans," "explores," "expects," "anticipates," "continue," "estimate," "projects," "intends," and similar phrases. Forward-looking statements involve risks and uncertainties that could cause actual results to differ from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of geopolitical conditions, competition, changes in technology and methods of marketing, and various other factors beyond the company's control.

For more information contact us at:
info@pharmacologyuniversity.com
817/528-2475 for English
214/733-0868 for Spanish

FEATURED Emerging Markets Report: A Case for Uranium May 26, 2022 10:07 AM

FEATURED Grove Inc. Upexi Division Launches Medicinal Mushroom Product Line Direct to Consumer and on Amazon May 26, 2022 9:07 AM

FEATURED SciSparc Announces Ethics Committee Approval to Conduct a Phase IIb Trial in Tourette Syndrome May 26, 2022 8:35 AM

Thunder Energies Signs $40 Million Funding Agreement TNRG May 26, 2022 4:30 PM

HNRC UPDATES ON SECOND $100 MILLION DOLLAR SPAC HNRC May 26, 2022 10:00 AM

Branded Legacy, Inc. Signs LOI To Acquire First Patent Thomas Pepper Johnson To Join Company's Executive Team BLEG May 26, 2022 8:30 AM

Dalrada Continues Upward Trajectory with 252% Growth in Third Quarter 2022 Financial Results DFCO May 26, 2022 8:00 AM

Atlanta Based Specialty Realty Group Reorganizes, Changes Business Plan & Leadership TNRG May 25, 2022 8:00 PM

OTC: ILUS, ILUS International (Ilustrato Pictures International Inc) Agrees Terms With an Acquisition Delivering Upwards of $100 Million in Annual Revenue ILUS May 25, 2022 11:52 AM

Branded Legacy, Inc. To Introduce New Delta 9 blend THC-0/Delta-8 Blend Gummies Sell Out Again BLEG May 25, 2022 8:30 AM

Goldshore Resources Announces Public (NSERC & MITACS) and Educational (Lakehead University) Tri-Party Institutional Partnership with Alliance Grant GSHR May 25, 2022 8:20 AM

Ultrack Systems Fully Acquires California Trucking Company M-Loan Inc. MJLB May 24, 2022 9:30 AM

SciSparc and Clearmind Medicine Inc. Collaboration Yields Positive Results for its Psychedelic Combination Treatment CMND May 24, 2022 8:36 AM

PSYC Teams Up with The Spore Group to Bring Industry-Leading, Psychedelic-Focused Events to Communities Across North America PSYC May 24, 2022 8:30 AM

Splash Beverage Group Broadens Reach through Agreement with Maryland's Buck Distributing SBEV May 24, 2022 8:12 AM